DekaBank Deutsche Girozentrale’s Epizyme, Inc EPZM Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-32,300	Closed	-$165K	–	1516
2021 Q3	$165K	Hold	32,300	–	–	﹤0.01%	1239
2021 Q2	$274K	Hold	32,300	–	–	﹤0.01%	1163
2021 Q1	$266K	Hold	32,300	–	–	﹤0.01%	1137
2020 Q4	$370K	Buy	32,300 +11,400	+55%	+$141K	﹤0.01%	1084
2020 Q3	$248K	Buy	+20,900	New	+$280K	﹤0.01%	1019
2019 Q4	–	Sell	-121,500	Closed	-$1.24M	–	1248
2019 Q3	$1.24M	Sell	121,500 -116,700	-49%	-$1.47M	0.01%	630
2019 Q2	$2.91M	Buy	238,200 +166,100	+230%	+$2.14M	0.01%	546
2019 Q1	$844K	Buy	72,100 +13,000	+22%	+$145K	0.01%	811
2018 Q4	$336K	Sell	59,100 -13,000	-18%	-$99.3K	﹤0.01%	897
2018 Q3	$844K	Sell	72,100 -2,000	-3%	-$22.8K	0.01%	828
2018 Q2	$982K	Buy	74,100 +15,000	+25%	+$233K	0.01%	754
2018 Q1	$1.04M	Buy	59,100 +25,800	+77%	+$436K	0.01%	713
2017 Q4	$461K	Hold	33,300	–	–	﹤0.01%	841
2017 Q3	$461K	Hold	33,300	–	–	﹤0.01%	847
2017 Q2	$518K	Hold	33,300	–	–	﹤0.01%	826
2017 Q1	$568K	Sell	33,300 -2,500	-7%	-$33.3K	0.01%	716
2016 Q4	$435K	Buy	35,800 +2,700	+8%	+$28.2K	﹤0.01%	684
2016 Q3	$314K	Hold	33,100	–	–	﹤0.01%	758
2016 Q2	$346K	Buy	33,100 +8,600	+35%	+$95.9K	﹤0.01%	756
2016 Q1	$282K	Buy	24,500 +3,500	+17%	+$35.4K	﹤0.01%	776
2015 Q4	$349K	Buy	21,000 +300	+1%	+$4.45K	﹤0.01%	761
2015 Q3	$266K	Buy	20,700 +1,000	+5%	+$20.2K	﹤0.01%	804
2015 Q2	$473K	Buy	19,700 +3,700	+23%	+$71.2K	0.01%	712
2015 Q1	$300K	Sell	16,000 -2,000	-11%	-$41.3K	﹤0.01%	823
2014 Q4	$321K	Sell	18,000 -1,700	-9%	-$39.7K	﹤0.01%	784
2014 Q3	$534K	Buy	19,700 +700	+4%	+$21.8K	0.01%	640
2014 Q2	$591K	Buy	19,000 +2,000	+12%	+$47.1K	0.01%	577
2014 Q1	$387K	Buy	+17,000	New	+$515K	0.01%	619

Other funds holding EPZM

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

DekaBank Deutsche Girozentrale's EPZM Position: Q4 2021 in Review

DekaBank Deutsche Girozentrale sold out of Epizyme, Inc (EPZM) in Q4 2021, closing a stake of 32,300 shares — an estimated $165K sold.

DekaBank Deutsche Girozentrale first reported a position in EPZM in Q1 2014 and held it in 28 quarters. The position peaked at $2.91M in Q2 2019. 132 funds tracked by Wall St. Rank hold EPZM as of Q4 2021.

DekaBank Deutsche Girozentrale reported no remaining Epizyme, Inc position as of Q4 2021 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 32,300 Epizyme, Inc shares in Q4 2021, an estimated $165K.
DekaBank Deutsche Girozentrale first reported a position in Epizyme, Inc in Q1 2014 and held it in 28 quarters.
DekaBank Deutsche Girozentrale's Epizyme, Inc position peaked at $2.91M in Q2 2019.
132 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2021.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2021, filed 2 Feb 2022.